Janone (ALTS) Competitors $9.57 -0.16 (-1.64%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ALTS vs. ANAB, ABCL, AVXL, KALV, ABUS, COGT, XNCR, EOLS, SION, and GHRSShould you be buying Janone stock or one of its competitors? The main competitors of Janone include AnaptysBio (ANAB), AbCellera Biologics (ABCL), Anavex Life Sciences (AVXL), KalVista Pharmaceuticals (KALV), Arbutus Biopharma (ABUS), Cogent Biosciences (COGT), Xencor (XNCR), Evolus (EOLS), Sionna Therapeutics (SION), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry. Janone vs. Its Competitors AnaptysBio AbCellera Biologics Anavex Life Sciences KalVista Pharmaceuticals Arbutus Biopharma Cogent Biosciences Xencor Evolus Sionna Therapeutics GH Research Janone (NASDAQ:ALTS) and AnaptysBio (NASDAQ:ANAB) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, community ranking, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations. Do insiders & institutionals have more ownership in ALTS or ANAB? 6.3% of Janone shares are held by institutional investors. 4.9% of Janone shares are held by company insiders. Comparatively, 33.5% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate ALTS or ANAB? AnaptysBio has a consensus target price of $42.38, suggesting a potential upside of 81.01%. Given AnaptysBio's stronger consensus rating and higher possible upside, analysts clearly believe AnaptysBio is more favorable than Janone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janone 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80 Does the MarketBeat Community believe in ALTS or ANAB? AnaptysBio received 380 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformJanoneN/AN/AAnaptysBioOutperform Votes38066.55% Underperform Votes19133.45% Which has preferable valuation and earnings, ALTS or ANAB? Janone has higher earnings, but lower revenue than AnaptysBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanone$18.05M9.26-$7.81MN/AN/AAnaptysBio$111.87M6.15-$163.62M-$4.85-4.83 Is ALTS or ANAB more profitable? Janone has a net margin of 0.00% compared to AnaptysBio's net margin of -289.75%. AnaptysBio's return on equity of -287.94% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets JanoneN/A -2,940.01% -39.81% AnaptysBio -289.75%-287.94%-37.25% Does the media prefer ALTS or ANAB? In the previous week, AnaptysBio had 4 more articles in the media than Janone. MarketBeat recorded 6 mentions for AnaptysBio and 2 mentions for Janone. AnaptysBio's average media sentiment score of 0.94 beat Janone's score of 0.22 indicating that AnaptysBio is being referred to more favorably in the news media. Company Overall Sentiment Janone Neutral AnaptysBio Positive Which has more volatility & risk, ALTS or ANAB? Janone has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500. SummaryAnaptysBio beats Janone on 11 of the 16 factors compared between the two stocks. Get Janone News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricJanonePharmaceutical IndustryFinance SectorNASDAQ ExchangeMarket Cap$167.04M$6.92B$11.72B$8.62BDividend YieldN/A2.55%5.66%4.17%P/E RatioN/A8.6723.0519.96Price / Sales9.26262.5326.86157.63Price / CashN/A65.8517.6034.64Price / Book-14.286.592.894.69Net Income-$7.81M$143.75M$1.04B$248.14M7 Day Performance-6.27%0.82%0.68%0.95%1 Month Performance44.56%12.09%1.15%5.74%1 Year PerformanceN/A4.46%540.95%14.73% Janone Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSJanoneN/A$9.57-1.6%N/AN/A$167.04M$18.05M0.00170Short Interest ↑Gap DownANABAnaptysBio1.7688 of 5 stars$23.52+7.6%$40.38+71.7%-2.9%$691.02M$111.87M-3.87100ABCLAbCellera Biologics2.6479 of 5 stars$2.31+7.9%$8.33+260.8%-7.9%$689.36M$23.11M-3.79500Options VolumeAVXLAnavex Life Sciences3.9254 of 5 stars$7.84+3.7%$44.00+461.2%+119.2%$669.32MN/A-14.2540Positive NewsKALVKalVista Pharmaceuticals4.0657 of 5 stars$13.35+3.3%$24.83+86.0%+6.0%$663.71MN/A-3.67100Positive NewsInsider TradeAnalyst RevisionHigh Trading VolumeABUSArbutus Biopharma2.2554 of 5 stars$3.45+2.7%$5.50+59.4%+10.2%$660.77M$6.40M-8.0290Positive NewsCOGTCogent Biosciences2.5086 of 5 stars$5.79+3.2%$14.57+151.7%-20.1%$659.23MN/A-2.3380Positive NewsXNCRXencor4.1911 of 5 stars$9.14+6.5%$29.50+222.8%-57.2%$650.50M$127.23M-2.86280Positive NewsHigh Trading VolumeEOLSEvolus4.1088 of 5 stars$9.96-0.1%$23.75+138.5%-11.7%$642.18M$275.46M-10.94170Positive NewsInsider TradeSIONSionna TherapeuticsN/A$14.48+3.7%$38.50+165.9%N/A$638.92MN/A0.0035GHRSGH Research1.7731 of 5 stars$12.08+4.5%$30.43+151.9%+4.0%$628.50MN/A-15.2910Analyst Revision Related Companies and Tools Related Companies ANAB Alternatives ABCL Alternatives AVXL Alternatives KALV Alternatives ABUS Alternatives COGT Alternatives XNCR Alternatives EOLS Alternatives SION Alternatives GHRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALTS) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janone Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALTS Stock Free ALTS Stock Alerts